Abstract:BACKGROUND:At present,some neurological imaging methods,including MRI,fMRI,2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile(18F-FDDNP)positron emission tomography(PET),are helpful but not specific for the diagnosis of Alzheimer disease(AD).18F-FDG is a special marker of beta-amyloid(Aβ),thus AD can be diagnosed by 18F-FDDNP PET at early period.OBJECTIVE:To evaluate the role of 18F-FDDNP PET in the diagnosis of AD,and establish reliable clinical biological indexes for the diagnosis of AD patients.DESIGN:A controlled analysis.SETTINGS:Department of Geriatric Neurology and Department of Nuclear Medicine,the General Hospital of Chinese PLA.PARTICIPANTS:Patients visiting the General Hospital of Chinese PLA from May 2004 to March 2005 were selected.Informed consents were obtained from all the participants.① AD group(n =7):(74.88±12.03)years old;Accorded with the criteria related to diagnosis of AD in NINCDS/ADRDA(National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer Disease and Related Disease Association)and revision of Diagnostic and statistical Manual(DSM-IV,4th ed.);brain CT or magnetic resonance imaging(MRI)examination displayed that inter-uncus distance of temporal lobes was ≥ 30 mm.② Vascular dementia group(n =6):(73.83±4.75)years old;Accorded with the diagnostic criteria of NINDS-AIREN(National Institute of Neurological Diseases and Stroke,USA)and DSM-IV for vascular dementia;Inter-uncus distance of temporal lobes < 30 mm.③ Control group(n =6):(71.17±3.71)years old;Without rarefaction of white matter;Intelligence examination was normal.METHODS:PET was performed in all the subjects.PET scanner type was SEIMENS ECAT EXACT HR.The tracer selected was 18F-FDDNP which had radiochemical purity higher than 95% and error of radioactivity measurement lower than 10%.The images were collected at 5,25 and 45 minutes after injection of 18F-FDDNP.Horizontal and coronary tomograms of brain were obtained after reconstruction.MAIN OUTCOME MEASURES:Characteristics of 18F-FDDNP brain PET images.RESULTS:① In the control group,signs of obvious atrophy of brain were not seen.At about 45 minutes,the radioactivity in cortex and subcortical nucleus groups was essentially cleared and the structures of brain could not be differentiated clearly.② In the vascular dementia group,brain atrophy and enlargement of ventricular system to various degrees could be seen.The clearance of radioactivity at three time points was similar to that in the control images.③ In the AD group,the brain was obviously atrophied and the ventricular system was enlarged.The clearance of radioactivity at the three time points was significantly different from the images of other two groups.The radioactivity in cortex and hippocampus was cleared slower.At 45 minutes,the gray matter could still be clearly differentiated from the white matter,but the radioactivity in corpus striatum and thalamus was not higher than that in cortex and much radioactivity retention could be seen in cortex and hippocampus.CONCLUSION:18F-FDDNP PET brain images can differentiate AD and vascular dementia,and it is an effective imaging index for the diagnosis of AD.

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease:a preliminary study

Classification and Interpretability of Mild Cognitive Impairment Based on Resting-State Functional Magnetic Resonance and Ensemble Learning.

Application of 18F-AV45 PET Imaging in Subtle Cognitive Decline and Mild Cognitive Impairment Patients

Decreased Bilateral FDG-PET Uptake and Inter-Hemispheric Connectivity in Multi-Domain Amnestic Mild Cognitive Impairment Patients: A Preliminary Study

18F-MK6240 PET imaging of tau protein in Alzheimer′s disease and cognitive correlation analysis

Analysis of PET and MRI in Alzheimer disease and mild cognitive impairment

Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease

Clinical application of brain perfusion SPECT/CT imaging with NeuroGamTM software in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

P1‐408: 18F‐FDG AND 18F‐AV45 POSITRON EMISSION TOMOGRAPHY IN ALZHEIMER'S DISEASE

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression

18F-FDDNP positron emission tomography in differentiating Alzheimer disease and vascular dementia

The Association Between Brain Metabolic Biomarkers Using 18F-FDG and Cognition and Vascular Risk Factors, as well as Its Usefulness in the Diagnosis and Staging of Alzheimer's Disease

The Investigation of Fluoro-deoxy-glucose PET in Alzheimer' S Disease and Mild Cognitive Impairment Using Statistical Parametric Mapping

Combining PET with MRI to improve predictions of progression from mild cognitive impairment to Alzheimer’s disease: an exploratory radiomic analysis study

Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer’s disease

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment

Classification of amyloid PET images using novel features for early diagnosis of Alzheimer's disease and mild cognitive impairment conversion

Combining PET with MRI to Improve Predictions of Progression from Mild Cognitive Impairment to Alzheimer's Disease: an Exploratory Radiomic Analysis Study

P2-249: Using brain 3D-MRI and 1H MRS imaging for early diagnosis of Alzheimer's disease

P-024: the Pattern and Severity of FDG Pet Abnormalities in Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative

Value of Visual Analysis and SUVR During 18F-AV45 PET/CT Imaging in the Diagnosis of Mild Cognitive Impairment and Alzheimer′s Disease